

## **TG101095 - Wet AMD Topical**

It is a topical tyrosine kinase inhibitor that specifically targets VEGFR, only tested in animal models.

JAK2 is a signalling kinase that acts downstream from erythropoietin, a glycoprotein hormone, which, along with VEGF, is involved in the pathogenesis of diabetic retinopathy.

The VEGF receptor and JAK2 inhibitor TG101095 dosed topically bid for two weeks significantly reduced CNV area in a laser-induced CNV mouse model<sup>(23)</sup>.

[View PDF](#)